Patents Examined by Johnnie R. Brown
  • Patent number: 5229373
    Abstract: An agent for prevention or prophylaxis of general toxic effects or chronic neurotoxic effects which are caused by the administration of antineoplastic agents, which is to be given to patients prior to administration of said antineoplastic agents and which comprises as an active ingredient a mixture of gangliosides GM.sub.1, GD.sub.1a, GD.sub.1b and GT.sub.1b.
    Type: Grant
    Filed: June 25, 1987
    Date of Patent: July 20, 1993
    Assignee: Fidia S.p.A.
    Inventor: Francesco della Valle
  • Patent number: 5227371
    Abstract: Administration of adenine nucleotides to a host is followed by their rapid degradation to adenosine and inorganic phosphate which promote increases in liver ATP pools. The turnover of expanded liver ATP pools supply the adenosine precursor for the subsequent expansions of red blood cell (total blood) and blood plasma (extracellular) ATP pools. Thus, the administration of AMP, ATP or their degradation products adenosine and inorganic phosphate to a host, achieve the beneficial increases in liver, total blood and blood plasma ATP levels.
    Type: Grant
    Filed: August 31, 1989
    Date of Patent: July 13, 1993
    Inventor: Eliezer Rapaport
  • Patent number: 5227479
    Abstract: The present invention relates to an efficient new route for the preparation of (+)-nojirimycin and (+)-1-deoxynojirimycin which involves the stereoselective reductive amination of 1,2-O-isopropylidene-5-oxo-.alpha.-D-glucuronolactone. The reductive amination uses particular oximes of the 5-oxo compound.
    Type: Grant
    Filed: November 14, 1990
    Date of Patent: July 13, 1993
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: Peter B. Anzeveno, Laura J. Creemer
  • Patent number: 5227480
    Abstract: Alkyl glycosides and alkyl oligoglycosides of low iodine color number can be preparedby acid-catalyzed condensation of saccharides in an aqueous solution with short-chain alcohols at elevated temperature in a counter-current reaction column.
    Type: Grant
    Filed: October 18, 1991
    Date of Patent: July 13, 1993
    Assignee: Huels Aktiengesellschaft - PB 15
    Inventors: Alfred Oberholz, John Kahsnitz, Stefan Schmidt
  • Patent number: 5227485
    Abstract: The A21 receptor extracelluar site and the A2 receptor extracellular site of adenosine analogues are structurally different and that binding orientations of adenosine or adenosine analogues are different at these sites and this may be used to determine their structure. Novel pyrimidine compounds are described.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: July 13, 1993
    Assignee: Griffith University
    Inventors: Ronald J. Quinn, Michael J. Dooley, Peter J. Scammells, Mary Chebib
  • Patent number: 5227291
    Abstract: Phosphoric acid derivatives represented by formula (I): ##STR1## wherein X is a halogen and R is --(CH.sub.2).sub.n CH.sub.3 (n=0 to 3), or salts thereof are stable to non-enzymatic hydrolysis and are capable of specifically reacting with acid phosphatase. Therefore, the activity of acid phosphatase in the sample can be determined extremely accurately by reacting said compound with a sample containing acid phosphatase and quantitatively determining the reaction product by colorimetry.
    Type: Grant
    Filed: September 10, 1991
    Date of Patent: July 13, 1993
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Katsumasa Kuroiwa, Katsuhiro Katayama, Toshihide Miura, Takeshi Nagasawa
  • Patent number: 5227370
    Abstract: The present invention provides pradimicin analogs which exhibit improved water solubility relative to parent compounds. These novel agents are useful in treatment of fungal infections.
    Type: Grant
    Filed: December 3, 1991
    Date of Patent: July 13, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hajime Kamachi, Seiji Iimura, Satsuki Okuyama, Shimpei Aburaki, Takayuki Naito, Yasutsugu Ueda, Leonard B. Crast, Jr., Amarendra B. Mikkilineni
  • Patent number: 5225529
    Abstract: Chemically and sterically pure synthetic amphiphilic glycoconjugates for neurological use of the formula (I): ##STR1## in which: the saccharide ring represents a monosaccharide such as glucose, galactose or mannose;X represents O or NH and, when X represents O, R is a choline radical whereas, when X represents NH, R is an amino acid or peptide radical; R' represents a saturated or unsaturated linear or branched C.sub.8 -C.sub.18 aliphatic chain, or a ##STR2## group where m is between 7 and 17 and; n is a whole number from 1 to 5.
    Type: Grant
    Filed: January 29, 1990
    Date of Patent: July 6, 1993
    Assignee: Farmhispania S.A.
    Inventors: Edoardo Butelman, Cesare Sirtori
  • Patent number: 5223404
    Abstract: A composition for testing periodontal diseases which diagnoses or prognosticates contraction or progress of the diseases or diagnoses the therapeutic value by promptly determining peptidase-like enzymatic activity in a specimen. The composition is a combination of a compound of the formula [1] or [2] or a mixture thereof, a chromogen and an oxidase:X-T-Pro-Y [1]orX'-Z'-Arg-Y' [2]wherein Pro is proline residue; Arg is arginine residue; X and X' are hydrogen or an amino protecting group, respectively; Y and Y' are a residue of a compound which can increase oxidation reaction rate of a chromogen with a oxidase in the presence of oxygen and is attached to the C-terminal of Pro or Arg, respectively; and T and Z' are an amino acid or peptide residue composed of 0 to 4 amino acids or their protected derivatives the C-terminal of which is attached to the N-terminal of Pro or Arg, respectively.
    Type: Grant
    Filed: January 11, 1991
    Date of Patent: June 29, 1993
    Assignees: Sunstar Kabushiki Kaisha, Kyowa Medex Co., Ltd.
    Inventors: Hirohisa Suido, Akira Miike, Kenji Hasegawa, Norihiko Kayahara, Toru Eguchi, Toshio Tatano, Koichi Nakashima
  • Patent number: 5223608
    Abstract: The present invention provides a process for preparing lactone intermediates to 2',2'-difluoronucleosides whereby reversion back to the lactone's open chain precursor is minimized and the desired erythro enantiomer can be selectively isolated from an enantiomeric mixture of erythro and threo lactones in crystalline form. Also provided is a process for producing 2'-deoxy-2',2'-difluoronucleosides in about a 1:1 .alpha./.beta. anomeric ratio, and processes for selectively isolating .beta.-2'-deoxy-2',2'-difluorocytidine, or an organic or inorganic acid addition salt thereof, from the 1:1 .alpha./.beta. mixture.
    Type: Grant
    Filed: July 12, 1990
    Date of Patent: June 29, 1993
    Assignee: Eli Lilly and Company
    Inventors: Ta-Sen Chou, Perry C. Heath
  • Patent number: 5223295
    Abstract: The present invention relates to a novel process for the elimination of steroid compounds contained in a substance of biological origin by complexing the steroidal compounds by means of a cyclodextrin, in an aqueous medium, under agitation at a temperature between 20.degree. and 80.degree. C. and then separating the complexes so formed.
    Type: Grant
    Filed: May 22, 1991
    Date of Patent: June 29, 1993
    Assignee: Asterol International
    Inventors: Jean-Pierre Maffrand, Jean Courregelongue
  • Patent number: 5223263
    Abstract: Compounds are disclosed for treating AIDS, herpes, and other viral infections by means of lipid derivatives of antiviral agents. The compounds consist of nucleoside analogues having antiviral activity which are linked, commonly through a phosphate group at the 5' position of the pentose residue, to one of a selected group of lipids. The lipophilic nature of these compounds provide advantages over the use of the nucleoside analogue alone. It also makes it possible to incorporate them into the lamellar structure of liposomes, either alone or combined with similar molecules. In the form of liposomes, these antiviral agents are preferentially taken up by macrophages and monocytes, cells which have been found to harbor the target HIV virus. Additional site specificity may be incorporated into the liposomes with the addition of ligands, such as monoclonal antibodies or other peptides or proteins which bind to viral proteins.
    Type: Grant
    Filed: June 28, 1989
    Date of Patent: June 29, 1993
    Assignee: Vical, Inc.
    Inventors: Karl Y. Hostetler, Raj Kumar, Louise M. Stuhmiller
  • Patent number: 5223609
    Abstract: Depolymerization of stabilized solutions of highly polymerized and nicked polydeoxyribonucleotides, as obtained through stabilizing aggregation of raw nucleic acids, the depolymerization being carried out by heating at controlled temperature and being controlled as a function of the variation of the reversible hyperchromicity, followed by the removal of the hydrogen bonds in the double stranded filaments and by thermal stabilization of the single stranded filaments, polydeoxyribonucleotide is obtained. The polydeoxyribonucleotide has the following formula of random sequence:P.sub.1-5, (dAp).sub.12-24, (dGp).sub.10-20, (dTp).sub.13-26, (dCp).sub.10-20,whereinP=phosphoric radicaldAp=deoxyadenylic monomerdGp=deoxyguanylic monomerdTp=deoxythymidylic monomerdCp=deoxycytidylic monomerand has well defined chemico-physical properties, reproducible in industrial production.
    Type: Grant
    Filed: May 26, 1992
    Date of Patent: June 29, 1993
    Assignee: Crinos Industria Farmacobiologica S.p.A.
    Inventors: Gianfranco Fedeli, Giuseppe Diamantini, Marisa Mantovani, Giuseppe Prino
  • Patent number: 5223618
    Abstract: Novel oligonucleotide analogs are provided having improved cellular uptake, improved resistance to nucleases, and good hybridization to target RNA. Such analogs are provided having substantially non-chiral, non-ionic linking functionalities between the sugars and sugar analogs thereof. In accordance with preferred embodiments, the 4' position of a sugar or sugar analog at one nucleoside is linked to the 3' position of a second sugar or sugar analog of a second nucleoside by a linking function that comprises a two- or three- carbon backbone chain. In accordance with preferred embodiments, the linking functions comprise the formula)--R.sub.1 --O where R.sub.1 comprises a two or three carbon backbone. Such linking functions also, preferably comprise ether functionalities to effect such linkage. Processes for the automated synthesis of oligonucleotide analogs are also provided.
    Type: Grant
    Filed: August 13, 1990
    Date of Patent: June 29, 1993
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Philip D. Cook, Yogesh S. Sanghvi
  • Patent number: 5221738
    Abstract: cDNA encoding a human .alpha..sub.2 -plasmin inhibitor precursor protein represented by an amino acid sequence from the -39th Met to the 452nd Lys in FIG. 1 of the accompanying drawings; an amino acid sequence of a human .alpha..sub.2 -plasmin inhibitor precursor represented by an amino acid sequence from the -39th Met to the 452nd Lys in FIG. 1 of the accompanying drawings; and genomic DNA encoding a human .alpha..sub.2 -plasmin inhibitor protein which is composed of exons II, III, IV, V, VI, VII, VIII, IX and X in FIG. 4 of the accompanying drawings, said exons being bonded to one another via introns.
    Type: Grant
    Filed: December 9, 1991
    Date of Patent: June 22, 1993
    Assignee: Teijin Limited
    Inventors: Yoshihiko Sumi, Yataro Ichikawa, Masami Murakami, Nobuo Aoki
  • Patent number: 5219843
    Abstract: The saccharides of formula I, ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 independently are optionally substituted acyl, are novel. They possess interesting pharmacological, especially immunostimulant, antiinflammatory and antitumor properties. They may be obtained by deprotection of a corresponding compound in protected form.
    Type: Grant
    Filed: November 22, 1991
    Date of Patent: June 15, 1993
    Assignee: Sandoz Ltd.
    Inventor: Ingolf Macher
  • Patent number: 5220003
    Type: Grant
    Filed: March 29, 1991
    Date of Patent: June 15, 1993
    Assignee: The Regents of the University of California
    Inventors: Michael E. Jung, John M. Gardiner
  • Patent number: 5219841
    Abstract: The present invention relates to a pharmaceutical composition for treating a heart disease which comprises a therapeutically effective amount of diadenosine 5',5'"-P.sup.1, P.sup.4 -tetraphosphate as an active ingredient in admixture with a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition is particularly characterized by having antiarrhythmic and coronary vasodilative activities. The present invention also relates to a method for treating a subject having a heart disease or particularly arrhythmia, which comprises administering to the subject an effective amount of the pharmaceutical composition.
    Type: Grant
    Filed: November 20, 1990
    Date of Patent: June 15, 1993
    Assignees: Fujirebio, Inc., Unitika Ltd.
    Inventors: Niro Inaba, Kunihiro Okamura, Tetsuaki Yamaura
  • Patent number: 5219840
    Abstract: N.sup.6, 2-disubstituted or 2-substituted 1'-desoxy-1'-(6-amino-9-purinyl)-.beta.-D-ribofuranuronic acid amides, N-substituted amides, N,N-disubstituted amides, thioamides, N-substituted thioamides and N,N-disubstituted thioamidesare effective against raised blood pressure.
    Type: Grant
    Filed: May 1, 1991
    Date of Patent: June 15, 1993
    Assignee: Sandoz Ltd.
    Inventors: Fulvio Gadient, Arnold Vogel
  • Patent number: 5220001
    Abstract: A compound of the following formula (I) exhibits an excellent antitumor activity ##STR1## wherein R.sub.1 and R.sub.2 represent hydrogen atom, respectively, or include both straight or branch chain alkylidene group of 1-10 carbon atoms; R.sub.3 represents hydrogen atoms, straight and branch chain alkyl group of 1-10 carbon atoms, straight or branch chain alkyloxycarbonyl group of 1-10 carbon atoms or 3-membered to 6-membered heterocycle containing one nitrogen atom with adjacent alkylene group such as pyrrolidine and N-butoxycarbonyl-pyrrolidine; R.sub.4 and R.sub.5 represent hydrogen atom or alkyl group of 1-5 carbon atoms, respectively; and n represents 0 or an integer of 1-10, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 22, 1990
    Date of Patent: June 15, 1993
    Assignees: Zaidan Hojim Biseibutsu Dong-A Pharm Co., Kagaku Kenkyukai
    Inventors: Kwang D. Ok, Jeong B. Park, Moon S. Kim